Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study

Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. Methods We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4...

Full description

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 64; no. 11; pp. 1699 - 1707
Main Authors Tubach, F., Ravaud, P., Martin‐Mola, E., Awada, H., Bellamy, N., Bombardier, C., Felson, D. T., Hajjaj‐Hassouni, N., Hochberg, M., Logeart, I., Matucci‐Cerinic, M., van de Laar, M., van der Heijde, D., Dougados, M.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2012
Wiley-Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. Methods We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4‐week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0–100 score. Results For the whole sample, the estimated MCII values for absolute change at 4 weeks were −17 (95% confidence interval [95% CI] −18, −15) for pain; −15 (95% CI −16, −14) for patient global assessment; −12 (95% CI −13, −11) for functional disability assessment; and −14 (95% CI −15, −14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients). Conclusion This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
AbstractList Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. Methods We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4‐week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0–100 score. Results For the whole sample, the estimated MCII values for absolute change at 4 weeks were −17 (95% confidence interval [95% CI] −18, −15) for pain; −15 (95% CI −16, −14) for patient global assessment; −12 (95% CI −13, −11) for functional disability assessment; and −14 (95% CI −15, −14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients). Conclusion This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
Abstract Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. Methods We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4‐week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0–100 score. Results For the whole sample, the estimated MCII values for absolute change at 4 weeks were −17 (95% confidence interval [95% CI] −18, −15) for pain; −15 (95% CI −16, −14) for patient global assessment; −12 (95% CI −13, −11) for functional disability assessment; and −14 (95% CI −15, −14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients). Conclusion This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4-week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0-100 score. For the whole sample, the estimated MCII values for absolute change at 4 weeks were -17 (95% confidence interval [95% CI] -18, -15) for pain; -15 (95% CI -16, -14) for patient global assessment; -12 (95% CI -13, -11) for functional disability assessment; and -14 (95% CI -15, -14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients). This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
OBJECTIVETo estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries.METHODSWe conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4-week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0-100 score.RESULTSFor the whole sample, the estimated MCII values for absolute change at 4 weeks were -17 (95% confidence interval [95% CI] -18, -15) for pain; -15 (95% CI -16, -14) for patient global assessment; -12 (95% CI -13, -11) for functional disability assessment; and -14 (95% CI -15, -14) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups ≥20 patients).CONCLUSIONThis work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
Author Martin‐Mola, E.
Ravaud, P.
Logeart, I.
Felson, D. T.
Tubach, F.
Hajjaj‐Hassouni, N.
van der Heijde, D.
Bombardier, C.
Bellamy, N.
Awada, H.
van de Laar, M.
Hochberg, M.
Matucci‐Cerinic, M.
Dougados, M.
Author_xml – sequence: 1
  givenname: F.
  surname: Tubach
  fullname: Tubach, F.
  email: florence.tubach@bch.aphp.fr
– sequence: 2
  givenname: P.
  surname: Ravaud
  fullname: Ravaud, P.
– sequence: 3
  givenname: E.
  surname: Martin‐Mola
  fullname: Martin‐Mola, E.
– sequence: 4
  givenname: H.
  surname: Awada
  fullname: Awada, H.
– sequence: 5
  givenname: N.
  surname: Bellamy
  fullname: Bellamy, N.
– sequence: 6
  givenname: C.
  surname: Bombardier
  fullname: Bombardier, C.
– sequence: 7
  givenname: D. T.
  surname: Felson
  fullname: Felson, D. T.
– sequence: 8
  givenname: N.
  surname: Hajjaj‐Hassouni
  fullname: Hajjaj‐Hassouni, N.
– sequence: 9
  givenname: M.
  surname: Hochberg
  fullname: Hochberg, M.
– sequence: 10
  givenname: I.
  surname: Logeart
  fullname: Logeart, I.
– sequence: 11
  givenname: M.
  surname: Matucci‐Cerinic
  fullname: Matucci‐Cerinic, M.
– sequence: 12
  givenname: M.
  surname: van de Laar
  fullname: van de Laar, M.
– sequence: 13
  givenname: D.
  surname: van der Heijde
  fullname: van der Heijde, D.
– sequence: 14
  givenname: M.
  surname: Dougados
  fullname: Dougados, M.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26674640$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22674853$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtv1DAUhQMqomXogj-AvEECqdPGdhIn7KoRL6kIqeqCXXTj3DBm_Ai2U5R_jzMzFIGEF_aR_d17j3WeZSfWWcyyFzS_pHnOrkD6S0ZFIR5nZ4yWdF1UZX3yoIuvp9l5CN_ztDira948zU4Zq0RRl_zs0eqzsspMhkidhAStZ6LM6HwEGxfl3T0aTBpsT0aIaq-lxDFCp5GE2YzRGRIiRCTKJiZtCzxMVkbl7HLptzgZiE71BHzcehVVuEjUbtYuKPuNhNHZftaHe7n1LpkhHcjdvt8F2S4dXYjo_qrvyVaN-3NnEf8B3pJbDJOOgQw-OQSSPhNGTKbukZj0oCwsBkEn91M_P8-eDKADnh_PVXb3_t3d5uP65suHT5vrm7UsGi7WgD00pejpwGosG8563uVN1WEpKtHVDdSClUzkFeNioAAl7YCLvqllhTmnfJW9PrRNdn5MGGJrVJCoNVh0U2gpTeVlzus8oW8OqEzOg8ehHb0y4OeW5u2SfpvSb_fpJ_blse3UGewfyN9ZJ-DVEYCQgh48WKnCH65KXFUsQ68O3E-lcf7_xPZ6c3sY_Qt4fM9_
CitedBy_id crossref_primary_10_1002_art_42831
crossref_primary_10_1093_rheumatology_ket240
crossref_primary_10_1177_1753193419867823
crossref_primary_10_1007_s00586_021_06911_3
crossref_primary_10_1186_s13018_023_03570_6
crossref_primary_10_1016_j_arth_2022_09_007
crossref_primary_10_1097_j_pain_0000000000001758
crossref_primary_10_1016_j_semarthrit_2020_07_010
crossref_primary_10_3899_jrheum_151244
crossref_primary_10_1002_14651858_CD014456
crossref_primary_10_1002_jbmr_3376
crossref_primary_10_1186_s12891_021_04921_2
crossref_primary_10_1136_rmdopen_2015_000140
crossref_primary_10_1177_1759720X211018605
crossref_primary_10_1002_art_41186
crossref_primary_10_1186_s13643_016_0363_9
crossref_primary_10_4137_CMAMD_S39432
crossref_primary_10_1186_s13643_016_0348_8
crossref_primary_10_1093_rheumatology_keu449
crossref_primary_10_1186_s13643_024_02467_7
crossref_primary_10_1097_BOT_0000000000002750
crossref_primary_10_1177_2325967119894747
crossref_primary_10_1093_rheumatology_kex396
crossref_primary_10_1002_acr_25212
crossref_primary_10_1002_14651858_CD014902
crossref_primary_10_2519_jospt_2019_8843
crossref_primary_10_1007_s12325_023_02661_4
crossref_primary_10_1002_ptr_7204
crossref_primary_10_1093_rheumatology_keaa768
crossref_primary_10_1186_s13075_020_02202_2
crossref_primary_10_1038_nrc3822
crossref_primary_10_1177_1947603517693043
crossref_primary_10_1136_bmjopen_2017_016020
crossref_primary_10_1016_j_cger_2021_11_012
crossref_primary_10_3899_jrheum_130313
crossref_primary_10_4276_030802213X13833255804513
crossref_primary_10_1007_s00402_021_04326_9
crossref_primary_10_1016_j_rhum_2016_05_004
crossref_primary_10_1177_1759720X211066233
crossref_primary_10_1093_rheumatology_kez202
crossref_primary_10_1136_rmdopen_2021_001994
crossref_primary_10_1177_1071100716660820
crossref_primary_10_1016_j_rehab_2020_10_005
crossref_primary_10_1177_03635465231179223
crossref_primary_10_7326_M20_0990
crossref_primary_10_3899_jrheum_141228
crossref_primary_10_1016_j_arth_2015_10_016
crossref_primary_10_1016_j_jhsa_2022_07_019
crossref_primary_10_1186_s13075_015_0807_y
crossref_primary_10_2340_17453674_2023_16906
crossref_primary_10_1093_rheumatology_keaa639
crossref_primary_10_2196_jmir_9465
crossref_primary_10_1186_s12891_023_06654_w
crossref_primary_10_1016_j_spinee_2016_06_010
crossref_primary_10_1186_s13075_015_0761_8
crossref_primary_10_1186_s12874_022_01600_1
crossref_primary_10_1016_j_arthro_2019_06_020
crossref_primary_10_1055_s_0043_1771010
crossref_primary_10_3899_jrheum_170424
crossref_primary_10_1007_s10067_019_04587_1
crossref_primary_10_1016_j_jbspin_2021_105306
crossref_primary_10_1002_acr_23176
crossref_primary_10_3899_jrheum_200872
crossref_primary_10_1002_acr_22401
crossref_primary_10_1002_acr_24264
crossref_primary_10_1177_1179544118782901
crossref_primary_10_2196_33489
crossref_primary_10_1016_j_msksp_2019_05_005
crossref_primary_10_1371_journal_pone_0229783
crossref_primary_10_1002_14651858_CD007911_pub3
crossref_primary_10_1093_pm_pnaa338
crossref_primary_10_1007_s00402_015_2336_1
crossref_primary_10_1002_acr_24816
crossref_primary_10_1016_j_jpain_2016_06_009
crossref_primary_10_1002_acr_22790
crossref_primary_10_1016_j_fas_2020_06_013
crossref_primary_10_1111_1756_185X_13709
crossref_primary_10_1016_j_ocarto_2023_100367
crossref_primary_10_1016_j_semarthrit_2018_03_013
crossref_primary_10_2106_JBJS_19_00817
crossref_primary_10_3390_diagnostics13040760
crossref_primary_10_17116_endoskop20202606149
crossref_primary_10_1186_s12955_016_0407_9
crossref_primary_10_1111_bjd_18922
crossref_primary_10_1136_rmdopen_2023_003111
crossref_primary_10_1007_s40744_023_00609_2
crossref_primary_10_1016_j_arth_2020_05_038
crossref_primary_10_1016_j_joca_2018_06_007
crossref_primary_10_1016_j_pmrj_2018_01_003
crossref_primary_10_1016_j_joca_2018_01_016
crossref_primary_10_1016_j_physio_2021_10_001
crossref_primary_10_2147_JPR_S441180
crossref_primary_10_1001_jama_2024_6063
crossref_primary_10_1016_j_jcot_2018_05_014
crossref_primary_10_1136_bmjopen_2016_015587
crossref_primary_10_1212_WNL_0000000000010574
crossref_primary_10_1016_j_ocarto_2023_100379
crossref_primary_10_1093_rheumatology_kez497
crossref_primary_10_1080_03009742_2016_1235226
crossref_primary_10_1136_bmjopen_2018_024184
crossref_primary_10_1093_rheumatology_keab934
crossref_primary_10_1007_s00402_015_2372_x
crossref_primary_10_1016_j_joca_2022_08_011
crossref_primary_10_1007_s10067_018_04414_z
crossref_primary_10_1177_0363546513514718
crossref_primary_10_1016_j_imu_2022_101113
crossref_primary_10_1080_17453674_2020_1733375
crossref_primary_10_1016_j_jbspin_2017_07_007
crossref_primary_10_1136_bmjopen_2015_009857
crossref_primary_10_1177_11795441211055882
crossref_primary_10_1007_s10067_019_04860_3
crossref_primary_10_1093_rap_rkab098
crossref_primary_10_1136_annrheumdis_2014_206829
crossref_primary_10_1186_s12913_023_10463_1
crossref_primary_10_1002_acr_22538
crossref_primary_10_1007_s10067_015_2874_5
crossref_primary_10_1136_rmdopen_2021_001839
crossref_primary_10_1007_s11136_022_03287_9
crossref_primary_10_1016_j_ocarto_2023_100382
crossref_primary_10_3899_jrheum_140337
crossref_primary_10_1007_s10067_014_2701_4
crossref_primary_10_1002_acr2_11422
crossref_primary_10_1093_rheumatology_keaa716
crossref_primary_10_1186_s12891_021_04690_y
crossref_primary_10_1016_j_joca_2024_06_008
crossref_primary_10_1016_j_rhum_2020_10_374
crossref_primary_10_1186_s13075_019_1833_y
crossref_primary_10_1007_s00192_020_04513_z
crossref_primary_10_1055_a_1206_6769
crossref_primary_10_1016_j_ocarto_2021_100230
crossref_primary_10_1136_rmdopen_2020_001546
crossref_primary_10_1155_2015_930756
crossref_primary_10_1080_03009742_2019_1637932
crossref_primary_10_1007_s40261_019_00756_x
crossref_primary_10_1016_j_joca_2017_04_001
crossref_primary_10_1186_s12906_022_03740_9
crossref_primary_10_1371_journal_pone_0073517
crossref_primary_10_1016_j_jphys_2019_05_011
crossref_primary_10_1136_bmjopen_2018_022337
crossref_primary_10_1002_acr_22558
crossref_primary_10_1093_rheumatology_keaa149
crossref_primary_10_1007_s00586_020_06365_z
crossref_primary_10_1371_journal_pone_0180014
crossref_primary_10_1002_acr_23766
crossref_primary_10_1177_0363546513494173
crossref_primary_10_2147_JPR_S258883
crossref_primary_10_1093_rheumatology_keu293
crossref_primary_10_1016_j_joca_2020_11_009
crossref_primary_10_1177_1753193418799568
crossref_primary_10_2340_17453674_2024_40817
crossref_primary_10_1002_ejp_1651
crossref_primary_10_1007_s00330_015_3740_1
crossref_primary_10_1016_j_joca_2015_07_001
crossref_primary_10_1007_s43465_020_00228_x
crossref_primary_10_1016_j_ocarto_2021_100174
crossref_primary_10_1053_j_jfas_2018_03_040
crossref_primary_10_1002_acr_24765
crossref_primary_10_1186_s12891_017_1441_4
crossref_primary_10_1186_s12891_021_04842_0
crossref_primary_10_1186_1471_2474_15_64
crossref_primary_10_1186_s13075_021_02590_z
crossref_primary_10_1016_j_spinee_2020_06_021
crossref_primary_10_1136_bmjopen_2018_027372
crossref_primary_10_1016_j_arthro_2016_09_024
crossref_primary_10_1136_bmjopen_2021_049298
crossref_primary_10_3899_jrheum_170181
crossref_primary_10_1177_10711007221112928
crossref_primary_10_1136_bmjsem_2021_001097
crossref_primary_10_1080_03009742_2020_1729404
crossref_primary_10_1001_jama_2020_2938
crossref_primary_10_2519_jospt_2020_9175
crossref_primary_10_1016_j_douler_2014_05_002
crossref_primary_10_1001_jamanetworkopen_2019_0018
crossref_primary_10_1038_nrc3822_c4
crossref_primary_10_1371_journal_pone_0292747
crossref_primary_10_1136_bmjopen_2020_047061
crossref_primary_10_1155_2017_7538604
crossref_primary_10_1055_s_0041_1723982
crossref_primary_10_1016_S1293_2965_21_45031_0
crossref_primary_10_3390_jcm11041087
crossref_primary_10_3390_ijerph20010311
crossref_primary_10_1002_acr2_11100
crossref_primary_10_14412_1996_7012_2020_2_90_96
crossref_primary_10_1016_j_jpain_2022_07_005
crossref_primary_10_2106_JBJS_RVW_22_00200
crossref_primary_10_1016_j_joca_2014_02_006
crossref_primary_10_2139_ssrn_4199937
crossref_primary_10_1111_anae_16150
crossref_primary_10_1016_S0140_6736_23_01572_6
crossref_primary_10_1111_papr_12477
crossref_primary_10_2147_JPR_S456202
crossref_primary_10_1016_j_joca_2023_08_013
crossref_primary_10_1016_j_ajem_2019_158489
crossref_primary_10_1016_j_rdc_2016_01_010
crossref_primary_10_1186_s13075_021_02550_7
crossref_primary_10_1177_2309499020938121
crossref_primary_10_1016_j_arthro_2016_05_014
crossref_primary_10_1136_annrheumdis_2018_214140
crossref_primary_10_1002_14651858_CD015378
crossref_primary_10_1186_s12891_020_03193_6
crossref_primary_10_1016_j_spinee_2020_05_004
crossref_primary_10_1371_journal_pone_0195653
crossref_primary_10_1016_j_joca_2015_04_004
crossref_primary_10_1097_MD_0000000000032091
crossref_primary_10_1016_j_jisako_2023_10_007
crossref_primary_10_1016_S2665_9913_22_00218_1
crossref_primary_10_1002_nop2_284
crossref_primary_10_1186_s12891_019_2478_3
crossref_primary_10_1136_bmjopen_2019_031142
crossref_primary_10_1002_art_40850
crossref_primary_10_1136_bmjopen_2022_067499
crossref_primary_10_2147_JPR_S321841
crossref_primary_10_1177_0363546519888644
crossref_primary_10_1080_17425247_2020_1783234
crossref_primary_10_1017_S0033291720003700
crossref_primary_10_2217_ijr_14_13
crossref_primary_10_1093_mr_road073
crossref_primary_10_1136_rmdopen_2020_001170
crossref_primary_10_1177_1049732318773714
crossref_primary_10_1186_s13643_016_0362_x
crossref_primary_10_1093_bja_aew466
crossref_primary_10_3389_fmed_2022_1032122
crossref_primary_10_3233_BMR_210068
crossref_primary_10_1016_j_spinee_2020_11_008
crossref_primary_10_1093_rheumatology_kead278
crossref_primary_10_1177_1759720X19893800
crossref_primary_10_1002_acr_22025
crossref_primary_10_1016_j_joca_2013_11_012
crossref_primary_10_1186_s13018_022_03125_1
crossref_primary_10_3109_17453674_2013_867782
crossref_primary_10_1097_PHM_0000000000000802
crossref_primary_10_1016_j_jor_2024_03_022
crossref_primary_10_1016_j_rhum_2017_11_003
crossref_primary_10_1016_j_arthro_2021_01_056
crossref_primary_10_1016_j_jbspin_2020_05_011
crossref_primary_10_1016_j_arthro_2020_10_016
crossref_primary_10_1002_acr_23227
crossref_primary_10_1002_14651858_CD010203_pub2
crossref_primary_10_1186_s13075_022_02892_w
crossref_primary_10_1186_s13063_022_06715_w
crossref_primary_10_47360_1995_4484_2023_361_368
crossref_primary_10_1016_j_jbspin_2020_09_003
crossref_primary_10_1016_j_joca_2015_03_007
crossref_primary_10_1016_j_rehab_2018_06_008
crossref_primary_10_1089_jwh_2015_5222
crossref_primary_10_1111_ejh_13965
crossref_primary_10_1136_annrheumdis_2013_205079
crossref_primary_10_1016_j_jclinepi_2018_05_007
crossref_primary_10_1093_rheumatology_kev282
crossref_primary_10_1007_s40744_019_0164_4
crossref_primary_10_1097_j_pain_0000000000001693
crossref_primary_10_1016_j_jbspin_2015_05_008
crossref_primary_10_1038_s41598_018_28782_3
crossref_primary_10_1136_annrheumdis_2014_205348
crossref_primary_10_1186_s13063_019_3977_0
crossref_primary_10_3899_jrheum_210889
crossref_primary_10_1002_14651858_CD015442
crossref_primary_10_1002_acr2_11141
crossref_primary_10_1002_msc_1681
crossref_primary_10_3390_jcm8060831
crossref_primary_10_1136_bmjopen_2019_035672
crossref_primary_10_1002_14651858_CD011321_pub2
crossref_primary_10_1016_S2665_9913_22_00129_1
crossref_primary_10_1080_03009742_2018_1447683
crossref_primary_10_1080_03009742_2023_2258644
crossref_primary_10_1007_s12445_017_0412_1
crossref_primary_10_1016_j_semarthrit_2021_04_006
crossref_primary_10_1016_j_berh_2021_101735
crossref_primary_10_1177_0363546520960461
crossref_primary_10_1038_nrrheum_2017_123
crossref_primary_10_1016_S1283_078X_21_45019_4
crossref_primary_10_1186_s12891_019_2748_0
crossref_primary_10_1177_0363546515595612
crossref_primary_10_1136_bmjopen_2021_056169
crossref_primary_10_2519_jospt_2024_12241
crossref_primary_10_1002_14651858_CD015450
crossref_primary_10_1055_s_0042_1743117
crossref_primary_10_1007_s40520_020_01515_1
crossref_primary_10_1093_rheumatology_keac040
crossref_primary_10_1093_rheumatology_keac161
crossref_primary_10_1186_s12891_016_1322_2
crossref_primary_10_1007_s10067_019_04574_6
crossref_primary_10_2106_JBJS_19_00695
crossref_primary_10_3390_nu9010042
crossref_primary_10_1080_13696998_2016_1176576
Cites_doi 10.1023/A:1015276414526
10.1002/art.1780310302
10.1002/art.1780331101
10.1136/ard.2004.022905
10.1097/00007632-198303000-00004
10.1136/ard.55.8.552
10.1016/0895-4356(94)90036-1
10.1136/ard.2004.023028
10.1186/1477-7525-4-69
10.1016/S0895-4356(01)00469-3
10.1016/0197-2456(89)90005-6
10.1016/S1063-4584(05)80101-3
10.1097/00002281-200203000-00006
10.1002/art.23527
10.3899/jrheum.090449
10.1097/00005650-200305000-00006
10.1002/acr.20131
10.1016/j.jclinepi.2008.09.012
10.1002/art.22110
10.1002/art.1780290816
10.1016/j.pain.2004.09.012
10.1016/S0895-4356(00)00204-3
10.1177/014662168300700301
10.2165/00019053-199712060-00002
10.1002/art.21615
10.1002/art.22469
10.1002/art.1780340502
10.1002/art.1780270401
10.1016/j.pain.2005.12.021
10.1136/bmj.332.7549.1080
10.1002/art.22342
10.1002/art.1780230202
10.1016/S0895-4356(03)00044-1
ContentType Journal Article
Copyright Copyright © 2012 by the American College of Rheumatology
2014 INIST-CNRS
Copyright © 2012 by the American College of Rheumatology.
Copyright_xml – notice: Copyright © 2012 by the American College of Rheumatology
– notice: 2014 INIST-CNRS
– notice: Copyright © 2012 by the American College of Rheumatology.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1002/acr.21747
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2151-4658
EndPage 1707
ExternalDocumentID 10_1002_acr_21747
22674853
26674640
ACR21747
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Sharp, & Dohme Chibret Laboratories, France
– fundername: Merck
GroupedDBID .3N
.GA
.Y3
0R~
10A
1OC
24P
31~
33P
4.4
50Z
51W
51X
52N
52O
52P
52R
52S
52T
52W
52X
53G
5VS
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCUV
ABIJN
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADMGS
ADOZA
ADXAS
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BRXPI
BY8
D-6
D-7
D-E
D-F
DCZOG
DR2
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
GODZA
H.X
HF~
HGLYW
HZ~
J0M
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N04
N05
NF~
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
QB0
ROL
SUPJJ
TEORI
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIK
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
ZZTAW
~WT
AAVGM
ABHUG
ACXME
ADAWD
ADDAD
AEUQT
AFVGU
AGJLS
IQODW
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4937-aeda957d1f28e5932d3b096be5767b89a87252706237f1aa51ba37d98c6e0313
IEDL.DBID DR2
ISSN 2151-464X
IngestDate Thu Jul 25 07:47:10 EDT 2024
Fri Aug 23 00:38:34 EDT 2024
Sat Sep 28 07:55:07 EDT 2024
Fri Nov 25 06:01:48 EST 2022
Sat Aug 24 00:53:08 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Knee
Knee osteoarthritis
Lumbar spine
Low back pain
Diseases of the osteoarticular system
Autoimmune disease
Inflammatory joint disease
Spine disease
Spondylarthropathy
Improvement
Pain
Dorsalgia
Rachialgia
Hip osteoarthritis
Degenerative disease
Ankylosing spondylitis
Human
Immunopathology
Rheumatology
Hand
Hip
Symptomatology
Chronic
Rheumatoid arthritis
Arthropathy
Dorsal spine
Osteoarthritis
Language English
License CC BY 4.0
Copyright © 2012 by the American College of Rheumatology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4937-aeda957d1f28e5932d3b096be5767b89a87252706237f1aa51ba37d98c6e0313
Notes Dr. Hochberg has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Amgen, AstraZeneca, Bristol Myers Squibb, Covidien, Eli Lilly, EMD Serono, Merck, Genentech, VCB, Theralogix, and Teva Pharmaceuticals, and (more than $10,000 each) from Bioiberica, NicOx, and Pfizer.
Dr. Ravaud has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Merck, Sharp, & Dohme.
Dr. Bombardier holds a Pfizer Research Chair and a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care.
Dr. Awada has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Ipsen and Novartis.
Dr. van der Heijde has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Amgen, AstraZeneca, Bristol Myers Squibb, Centocor, Chugai, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi‐Aventis, Schering Plough, UCB, and Wyeth.
Dr. Matucci‐Cerinic has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Bristol Myers Squibb, Pfizer, and Actelion.
Dr. Dougados has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Merck.
Dr. Bombardier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott Canada, AstraZeneca, BioGen, Pfizer, Merck (Schering), and Janssen (Merck), (more than $10,000) from Abbott International, and served on the advisory boards for Bristol Myers Squibb, Pfizer, Pfizer (Wyeth), Merck (Schering), Janssen (Merck), and Takeda.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://ris.utwente.nl/ws/files/6805969/minimum.pdf
PMID 22674853
PQID 1125250380
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1125250380
crossref_primary_10_1002_acr_21747
pubmed_primary_22674853
pascalfrancis_primary_26674640
wiley_primary_10_1002_acr_21747_ACR21747
PublicationCentury 2000
PublicationDate November 2012
PublicationDateYYYYMMDD 2012-11-01
PublicationDate_xml – month: 11
  year: 2012
  text: November 2012
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: Hoboken, NJ
– name: United States
PublicationTitle Arthritis care & research (2010)
PublicationTitleAlternate Arthritis Care Res (Hoboken)
PublicationYear 2012
Publisher John Wiley & Sons, Inc
Wiley-Blackwell
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley-Blackwell
References 2002; 14
1990; 33
2009; 62
1991; 34
1984; 27
2006; 54
1995; 15
2006; 55
2005; 113
1983; 7
1980; 23
1997; 24
2002; 11
2002; 55
2008; 59
2005; 64
1994; 47
1983; 8
2006; 4
2001; 28
1988; 31
2007; 34
2003; 30
2006; 332
2007; 57
2010; 62
1994; 21
1996; 55
2003; 56
1989; 10
1997; 12
2000; 53
2011; 41
2006; 121
1986; 29
2005; 32
1996; 4
2003; 41
2009; 37
e_1_2_8_27_2
e_1_2_8_28_2
e_1_2_8_29_2
e_1_2_8_23_2
e_1_2_8_24_2
e_1_2_8_25_2
e_1_2_8_26_2
e_1_2_8_9_2
Calin A (e_1_2_8_35_2) 1994; 21
Bellamy N (e_1_2_8_37_2) 1995; 15
e_1_2_8_2_2
e_1_2_8_4_2
e_1_2_8_6_2
e_1_2_8_5_2
e_1_2_8_8_2
e_1_2_8_7_2
Garrett S (e_1_2_8_34_2) 1994; 21
e_1_2_8_42_2
e_1_2_8_41_2
e_1_2_8_22_2
Tubach F (e_1_2_8_20_2) 2007; 34
e_1_2_8_16_2
e_1_2_8_17_2
e_1_2_8_38_2
e_1_2_8_18_2
e_1_2_8_19_2
e_1_2_8_12_2
e_1_2_8_13_2
Bellamy N (e_1_2_8_3_2) 1997; 24
e_1_2_8_14_2
e_1_2_8_15_2
e_1_2_8_36_2
Wells G (e_1_2_8_39_2) 2001; 28
Wells G (e_1_2_8_44_2) 2003; 30
Bellamy N (e_1_2_8_43_2) 2011; 41
e_1_2_8_31_2
Tubach F (e_1_2_8_21_2) 2005; 32
e_1_2_8_30_2
Wells G (e_1_2_8_40_2) 2003; 30
e_1_2_8_10_2
e_1_2_8_33_2
e_1_2_8_11_2
e_1_2_8_32_2
References_xml – volume: 24
  start-page: 799
  year: 1997
  end-page: 802
  article-title: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III
  publication-title: J Rheumatol
– volume: 8
  start-page: 141
  year: 1983
  end-page: 4
  article-title: A study of the natural history of back pain. Part I. Development of a reliable and sensitive measure of disability in low‐back pain
  publication-title: Spine
– volume: 37
  start-page: 26
  year: 2009
  end-page: 31
  article-title: Identification of cutpoints for acceptable health status and important improvement in patient‐reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
  publication-title: J Rheumatol
– volume: 121
  start-page: 151
  year: 2006
  end-page: 7
  article-title: Patient‐perceived satisfactory improvement (PPSI): interpreting meaningful change in pain from the patient's perspective
  publication-title: Pain
– volume: 332
  start-page: 1080
  year: 2006
  article-title: The cost of dichotomising continuous variables
  publication-title: BMJ
– volume: 30
  start-page: 1110
  year: 2003
  end-page: 1
  article-title: MCID/low disease activity state workshop: low disease activity state in rheumatoid arthritis
  publication-title: J Rheumatol
– volume: 55
  start-page: 239
  year: 2002
  end-page: 44
  article-title: Measurement of fatigue: determining minimally important clinical differences
  publication-title: J Clin Epidemiol
– volume: 10
  start-page: 407
  year: 1989
  end-page: 15
  article-title: Measurement of health status: ascertaining the minimal clinically important difference
  publication-title: Control Clin Trials
– volume: 54
  start-page: 551
  year: 2006
  end-page: 6
  article-title: Validity, factor structure, and clinical relevance of the AUSCAN osteoarthritis hand index
  publication-title: Arthritis Rheum
– volume: 31
  start-page: 315
  year: 1988
  end-page: 24
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 14
  start-page: 109
  year: 2002
  end-page: 14
  article-title: Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research
  publication-title: Curr Opin Rheumatol
– volume: 55
  start-page: 526
  year: 2006
  end-page: 30
  article-title: Feeling good rather than feeling better matters more to patients
  publication-title: Arthritis Rheum
– volume: 53
  start-page: 895
  year: 2000
  end-page: 907
  article-title: Which chronic conditions are associated with better or poorer quality of life?
  publication-title: J Clin Epidemiol
– volume: 7
  start-page: 249
  year: 1983
  end-page: 53
  article-title: The cost of dichotomization
  publication-title: Appl Psychol Meas
– volume: 30
  start-page: 1115
  year: 2003
  end-page: 8
  article-title: MCID/low disease activity state workshop: summary, recommendations, and research agenda
  publication-title: J Rheumatol
– volume: 11
  start-page: 207
  year: 2002
  end-page: 21
  article-title: Meaningful change in cancer‐specific quality of life scores: differences between improvement and worsening
  publication-title: Qual Life Res
– volume: 64
  start-page: 29
  year: 2005
  end-page: 33
  article-title: Evaluation of clinically relevant changes in patient‐reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement
  publication-title: Ann Rheum Dis
– volume: 12
  start-page: 621
  year: 1997
  end-page: 6
  article-title: Reassessing quality‐of‐life instruments in the evaluation of new drugs
  publication-title: Pharmacoeconomics
– volume: 62
  start-page: 725
  year: 2009
  end-page: 8
  article-title: The variability in MCII and PASS estimates did not have an impact on treatment effect estimates
  publication-title: J Clin Epidemiol
– volume: 55
  start-page: 552
  year: 1996
  end-page: 7
  article-title: Recommendations for the registration of drugs used in the treatment of osteoarthritis
  publication-title: Ann Rheum Dis
– volume: 59
  start-page: 553
  year: 2008
  end-page: 60
  article-title: Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial
  publication-title: Arthritis Rheum
– volume: 23
  start-page: 137
  year: 1980
  end-page: 45
  article-title: Measurement of patient outcome in arthritis
  publication-title: Arthritis Rheum
– volume: 47
  start-page: 81
  year: 1994
  end-page: 7
  article-title: Determining a minimal important change in a disease‐specific quality of life questionnaire
  publication-title: J Clin Epidemiol
– volume: 41
  start-page: 23
  issue: Suppl
  year: 2011
  article-title: Comparison of transformed visual analogue and native numerical rating scaled patient responses to the WOMAC Index
  publication-title: Int Med J
– volume: 57
  start-page: 133
  year: 2007
  end-page: 9
  article-title: Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis
  publication-title: Arthritis Rheum
– volume: 34
  start-page: 505
  year: 1991
  end-page: 14
  article-title: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip
  publication-title: Arthritis Rheum
– volume: 29
  start-page: 1039
  year: 1986
  end-page: 49
  article-title: Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee
  publication-title: Arthritis Rheum
– volume: 21
  start-page: 2281
  year: 1994
  end-page: 5
  article-title: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index
  publication-title: J Rheumatol
– volume: 4
  start-page: 69
  year: 2006
  article-title: How a well‐grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure
  publication-title: Health Qual Life Outcomes
– volume: 33
  start-page: 1601
  year: 1990
  end-page: 10
  article-title: The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand
  publication-title: Arthritis Rheum
– volume: 64
  start-page: 34
  year: 2005
  end-page: 7
  article-title: Evaluation of clinically relevant states in patient‐reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state
  publication-title: Ann Rheum Dis
– volume: 41
  start-page: 597
  year: 2003
  end-page: 8
  article-title: Interpreting health‐related quality of life scores: the simple rule of seven may not be so simple
  publication-title: Med Care
– volume: 32
  start-page: 2025
  year: 2005
  end-page: 9
  article-title: Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues
  publication-title: J Rheumatol
– volume: 21
  start-page: 2286
  year: 1994
  end-page: 91
  article-title: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
  publication-title: J Rheumatol
– volume: 28
  start-page: 452
  year: 2001
  end-page: 4
  article-title: Minimal clinically important difference module: summary, recommendations, and research agenda
  publication-title: J Rheumatol
– volume: 113
  start-page: 9
  year: 2005
  end-page: 19
  article-title: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations
  publication-title: Pain
– volume: 55
  start-page: 960
  year: 2006
  end-page: 3
  article-title: Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis
  publication-title: Arthritis Rheum
– volume: 4
  start-page: 217
  year: 1996
  end-page: 43
  article-title: Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop
  publication-title: Osteoarthritis Cartilage
– volume: 62
  start-page: 826
  year: 2010
  end-page: 34
  article-title: Thresholds of patient‐reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics
  publication-title: Arthritis Care Res (Hoboken)
– volume: 34
  start-page: 1188
  year: 2007
  end-page: 93
  article-title: Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders
  publication-title: J Rheumatol
– volume: 15
  start-page: 1833
  year: 1995
  end-page: 40
  article-title: Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthitis of the hip or knee
  publication-title: J Rheumatol
– volume: 27
  start-page: 361
  year: 1984
  end-page: 8
  article-title: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria
  publication-title: Arthritis Rheum
– volume: 56
  start-page: 395
  year: 2003
  end-page: 407
  article-title: Defining clinically meaningful change in health‐related quality of life
  publication-title: J Clin Epidemiol
– ident: e_1_2_8_9_2
  doi: 10.1023/A:1015276414526
– ident: e_1_2_8_28_2
  doi: 10.1002/art.1780310302
– ident: e_1_2_8_30_2
  doi: 10.1002/art.1780331101
– volume: 21
  start-page: 2286
  year: 1994
  ident: e_1_2_8_34_2
  article-title: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
  publication-title: J Rheumatol
  contributor:
    fullname: Garrett S
– ident: e_1_2_8_8_2
  doi: 10.1136/ard.2004.022905
– ident: e_1_2_8_38_2
  doi: 10.1097/00007632-198303000-00004
– volume: 34
  start-page: 1188
  year: 2007
  ident: e_1_2_8_20_2
  article-title: Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders
  publication-title: J Rheumatol
  contributor:
    fullname: Tubach F
– ident: e_1_2_8_4_2
  doi: 10.1136/ard.55.8.552
– ident: e_1_2_8_13_2
  doi: 10.1016/0895-4356(94)90036-1
– ident: e_1_2_8_14_2
  doi: 10.1136/ard.2004.023028
– ident: e_1_2_8_18_2
  doi: 10.1186/1477-7525-4-69
– ident: e_1_2_8_11_2
  doi: 10.1016/S0895-4356(01)00469-3
– ident: e_1_2_8_12_2
  doi: 10.1016/0197-2456(89)90005-6
– volume: 21
  start-page: 2281
  year: 1994
  ident: e_1_2_8_35_2
  article-title: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index
  publication-title: J Rheumatol
  contributor:
    fullname: Calin A
– volume: 30
  start-page: 1115
  year: 2003
  ident: e_1_2_8_44_2
  article-title: MCID/low disease activity state workshop: summary, recommendations, and research agenda
  publication-title: J Rheumatol
  contributor:
    fullname: Wells G
– ident: e_1_2_8_2_2
  doi: 10.1016/S1063-4584(05)80101-3
– ident: e_1_2_8_6_2
  doi: 10.1097/00002281-200203000-00006
– ident: e_1_2_8_25_2
  doi: 10.1002/art.23527
– ident: e_1_2_8_22_2
  doi: 10.3899/jrheum.090449
– ident: e_1_2_8_5_2
  doi: 10.1097/00005650-200305000-00006
– ident: e_1_2_8_26_2
  doi: 10.1002/acr.20131
– ident: e_1_2_8_41_2
  doi: 10.1016/j.jclinepi.2008.09.012
– ident: e_1_2_8_15_2
  doi: 10.1002/art.22110
– volume: 32
  start-page: 2025
  year: 2005
  ident: e_1_2_8_21_2
  article-title: Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues
  publication-title: J Rheumatol
  contributor:
    fullname: Tubach F
– ident: e_1_2_8_32_2
  doi: 10.1002/art.1780290816
– volume: 28
  start-page: 452
  year: 2001
  ident: e_1_2_8_39_2
  article-title: Minimal clinically important difference module: summary, recommendations, and research agenda
  publication-title: J Rheumatol
  contributor:
    fullname: Wells G
– ident: e_1_2_8_19_2
  doi: 10.1016/j.pain.2004.09.012
– volume: 30
  start-page: 1110
  year: 2003
  ident: e_1_2_8_40_2
  article-title: MCID/low disease activity state workshop: low disease activity state in rheumatoid arthritis
  publication-title: J Rheumatol
  contributor:
    fullname: Wells G
– ident: e_1_2_8_42_2
  doi: 10.1016/S0895-4356(00)00204-3
– volume: 15
  start-page: 1833
  year: 1995
  ident: e_1_2_8_37_2
  article-title: Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthitis of the hip or knee
  publication-title: J Rheumatol
  contributor:
    fullname: Bellamy N
– ident: e_1_2_8_16_2
  doi: 10.1177/014662168300700301
– volume: 41
  start-page: 23
  year: 2011
  ident: e_1_2_8_43_2
  article-title: Comparison of transformed visual analogue and native numerical rating scaled patient responses to the WOMAC Index
  publication-title: Int Med J
  contributor:
    fullname: Bellamy N
– ident: e_1_2_8_10_2
  doi: 10.2165/00019053-199712060-00002
– ident: e_1_2_8_36_2
  doi: 10.1002/art.21615
– ident: e_1_2_8_27_2
  doi: 10.1002/art.22469
– ident: e_1_2_8_31_2
  doi: 10.1002/art.1780340502
– ident: e_1_2_8_29_2
  doi: 10.1002/art.1780270401
– ident: e_1_2_8_24_2
  doi: 10.1016/j.pain.2005.12.021
– ident: e_1_2_8_17_2
  doi: 10.1136/bmj.332.7549.1080
– volume: 24
  start-page: 799
  year: 1997
  ident: e_1_2_8_3_2
  article-title: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III
  publication-title: J Rheumatol
  contributor:
    fullname: Bellamy N
– ident: e_1_2_8_23_2
  doi: 10.1002/art.22342
– ident: e_1_2_8_33_2
  doi: 10.1002/art.1780230202
– ident: e_1_2_8_7_2
  doi: 10.1016/S0895-4356(03)00044-1
SSID ssj0000328839
Score 2.574294
Snippet Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5...
To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic...
Abstract Objective To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in...
OBJECTIVETo estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1699
SubjectTerms Adult
Aged
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - psychology
Arthritis, Rheumatoid - therapy
Back Pain - diagnosis
Back Pain - psychology
Back Pain - therapy
Biological and medical sciences
Chronic Pain - diagnosis
Chronic Pain - psychology
Chronic Pain - therapy
Cohort Studies
Disability Evaluation
Diseases of the osteoarticular system
Diseases of the spine
Female
Humans
Inflammatory joint diseases
Internationality
Male
Medical sciences
Middle Aged
Osteoarthritis
Osteoarthritis, Hip - diagnosis
Osteoarthritis, Hip - psychology
Osteoarthritis, Hip - therapy
Osteoarthritis, Knee - diagnosis
Osteoarthritis, Knee - psychology
Osteoarthritis, Knee - therapy
Patient Satisfaction - statistics & numerical data
Prospective Studies
Rheumatic Diseases - diagnosis
Rheumatic Diseases - psychology
Rheumatic Diseases - therapy
Severity of Illness Index
Spondylitis, Ankylosing - diagnosis
Spondylitis, Ankylosing - psychology
Spondylitis, Ankylosing - therapy
Treatment Outcome
Title Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr.21747
https://www.ncbi.nlm.nih.gov/pubmed/22674853
https://search.proquest.com/docview/1125250380
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ni9swEFWXPZSW0u-P9GOZlh56WGcdWY6c9rQsXZZCeghbyKFgJEsmJrEdYvuQ_vrOSHGWLC2UXhxjRkaOn6w3kt4TYx9jG0aWx1lgcysDYY0MtJJZkMtQyFiPlA1J4Dz9Pr76Ib7N4_kR-9JrYbw_xH7AjVqG-15TA1e6ObsxDVXZZkh8mpTkZKRHhGjG9-Mr5BOXuI3EqFMLxFjMe2OhkJ_tCx90Rw_WqsF_JvdbWvyJcx5SWNcHXT5iP_va-6Uny2HX6mH265ax438-3mP2cMdN4dyD6Qk7stVTdne6m31_duf-tKiKsiuhl1OutlCUjsBXLZ1tauc-3oKqDOwcW0FltHKGFFrQbMt1W5fgVExQVBiDBwqm7pUgQhc3C9shj64LA4jrhXNdOsWo5XZV08gG0Kpes13565l39wWtsqW73ynQZACQeKU-KG9gUazd77Ky9lbAZ5jZplu1DZDgBhTgw_QqVHCrLvthU3COvM_Z9eXX64urYLeZRJAJpGCBskZNYmlGOU9sjKzVRBrTN20x4ZI6mahE8pjLEOmgzEdKxSOtImkmSTa25G_5gh1XdWVfMQgj_IYJhZmqijDdE5Ox0InIkSgaq5HRDtiHHlLp2luGpN4cmqf4VlP3Vgfs5ABs-0gkTBLBGg7Y-x59KbZ4msZRla27BnM2TnPRUYIxLz0sb0pz2jwmxjp8cuD6ewXS84uZO3n976Fv2D3ki9xLMd-y43bT2XfIyVp94hrfb3WoOPg
link.rule.ids 315,786,790,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwEDZjSAyE-Dmg_BgH4oGHpUsTu04RL9NgKrDuoSpSX1BkJ44atUmqJnkofz13TtOpE0iIlzSKzpHT3MXfnf19Zuy9MK5vPBE5JjHS4SaWjlYychLpcil0TxmXCM6jy_7wB_82FdM99qnlwjT6ENuCG0WG_V5TgFNB-uRKNVRFqy4BanmT3cJwFxSWn8fetsJCSnGB3UqMhjWH9_m0lRZyvZNt650B6d5SlfjfJM2mFn9Cnbsg1o5C5w_Yz7b_zeKTebeudDf6dU3a8X8f8CG7v4GncNr40yO2Z_LH7PZoMwH_5MbdUZqnWZ1By6hcrCHNLIbPKzpbFVaAvAKVx7ARbQUV0eIZImlBuc6WVZGBJTJBmqMNHsiYRljyErq4mpkaoXSRxoCuPbPCS8doNV8vCipuAC3sjdeL5nrUCPyCVtHc3u8YaD4AiL9S7LSPYZYu7e88N-aawUcYm7JeVCUQ5wYU4MO0RFSwCy_byilYUd5DNjn_MjkbOpv9JJyIIwpzlInVQMi4l3iBEQhcY19jBqcN5lxSBwMVSE940kVEKJOeUqKnlS_jQRD1DUlcPmX7eZGb5wxcHz9jXGGyqnzM-Pigz3XAE8SKsdEIajvsXetT4bJRDQkbfWgvxLca2rfaYUc73ra1RMwk0VvdDnvbul-IQU8zOSo3RV1i2ubRdLQfoM2zxi-vWnu0f4zAPnyw3vX3DoSnZ2N78uLfTd-wg-FkdBFefL38_pLdQfjoNczMV2y_WtXmNUK0Sh_ZSPwN2pM9GA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFNW6DkrH2He37KO7G3vYQ506shw521NpF7qPlBFayMPASJZMTBI7JPZD9ut3rxynpGww9uIYc2Xk-Mg6V9I5Yux9aP3A8jDxbGqlJ6yRnlYy8VLpCxnqjrI-CZwHF93zK_F1FI522KdGC1P7Q2wG3KhluO81NfC5SY-vTUNVsmgTn5a32R3RDThlXmdDvhlgIaO4yO0kRr2aJ7pi1DgL-fx4U3qrP7o3V0v8a9J6T4s_kc5tDus6of4D9rOpfr32ZNKuSt1Oft1wdvzP53vI7q_JKZzUaHrEdmz-mO0N1tPvT27dHWR5Nqtm0OgppyvIZo7B5yWdLQpnP16Cyg2sLVtBJbR0hiRasFzN5mUxAydjgizHGDxQMPWvhBG6uBjbCol0kRlAYI-d7dIRRk1W04KGNoCW9ZrVtL6e1Pa-oFUycfc7ApoNAFKvFFvlDYyzufud5NbeCPgIQ7uspuUSSHEDCvBhGhkquGWXzbgpOEvep-yy__ny9Nxb7ybhJQI5mKesUb1Qmk7KIxsibTWBxvxNW8y4pI56KpI85NJHPijTjlJhR6tAml6UdC0ZXB6w3bzI7XMGfoAfMaEwVVUB5nui1xU6EikyRWM1UtoWe9dAKp7XniFx7Q7NY3yrsXurLXa4BbZNJDImiWD1W-xtg74YmzzN46jcFtUSkzZOk9FBhDHPalhel-a0e0yIdfjgwPX3CsQnp0N38uLfQ9-wvR9n_fj7l4tvL9k-ckdeyzJfsd1yUdnXyM9Kfeja4W8I1DvH
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Minimum+clinically+important+improvement+and+patient+acceptable+symptom+state+in+pain+and+function+in+rheumatoid+arthritis%2C+ankylosing+spondylitis%2C+chronic+back+pain%2C+hand+osteoarthritis%2C+and+hip+and+knee+osteoarthritis%3A+Results+from+a+prospective+multinational+study&rft.jtitle=Arthritis+care+%26+research+%282010%29&rft.au=Tubach%2C+F.&rft.au=Ravaud%2C+P.&rft.au=Martin%E2%80%90Mola%2C+E.&rft.au=Awada%2C+H.&rft.date=2012-11-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=2151-464X&rft.eissn=2151-4658&rft.volume=64&rft.issue=11&rft.spage=1699&rft.epage=1707&rft_id=info:doi/10.1002%2Facr.21747&rft.externalDBID=10.1002%252Facr.21747&rft.externalDocID=ACR21747
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2151-464X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2151-464X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2151-464X&client=summon